CD274 and non-small cell lung carcinoma: In the phase Ia/b study, the efficacy of the anti-TIM-3 monoclonal antibody LY3321367 in patients with non-small-cell lung cancer varied depending on the response to anti-PD-1/anti-PDL-1 therapy; in patients refractory to anti-PD-1/anti-PDL-1 treatment, the objective response rate to monotherapy was 0% (ORR).